WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
Wang Yi reiterates Beijing's desire for peaceful reunification with Taiwan
Profile: Xi Jinping the reformer
SOEs crucial to China's economic growth
Minister pledges to improve security of State benefits
Wang Yi: U.S. must be rational about China
Xizang professor promotes plateau ecology
Investigators return to Long Island home of Gilgo Beach serial killing suspect
Resolving border issue 'in common interest' of China and India: Chinese FM
Amtrak train hits pickup truck in upstate New York, 3 dead including child
Beijing's efforts seen as key to resolving crisis